However, similar to patients with CML, the fraction of LinnegSca-1+KIT+CD48negCD150+ hematopoietic stem cells was not reduced by dasatinib treatment, suggesting that these cells are not oncogene-addicted. The gene discussed is KIT; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.